SARS virus hyperimmune globulin - Cangene

Drug Profile

SARS virus hyperimmune globulin - Cangene

Alternative Names: Coronavirus virus hyperimmune globulin - Cangene

Latest Information Update: 28 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cangene Corporation
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronavirus infections

Most Recent Events

  • 21 Feb 2014 Emergent BioSolutions acquires Cangene Corporation
  • 19 Jun 2007 This programme is still active, although the future need of a SARS immune globulin is unknown
  • 20 Oct 2003 Cangene has entered into a research and development agreement with the NIAID to develop a hyperimmune for the potential treatment of SARS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top